Publication:
Significance of PD1 Alternative Splicing in Celiac Disease as a Novel Source for Diagnostic and Therapeutic Target.

dc.contributor.authorPonce de León, Candelaria
dc.contributor.authorLorite, Pedro
dc.contributor.authorLópez-Casado, Miguel Ángel
dc.contributor.authorBarro, Francisco
dc.contributor.authorPalomeque, Teresa
dc.contributor.authorTorres, María Isabel
dc.date.accessioned2023-02-09T11:42:39Z
dc.date.available2023-02-09T11:42:39Z
dc.date.issued2021-06-16
dc.description.abstractWe have focused on the alteration of the PD-1/PD-L1 pathway in celiac disease and discussed the roles of the PD1 pathway in regulating the immune response. We explored the idea that the altered mRNA splicing process in key regulatory proteins could represent a novel source to identify diagnostic, prognostic, and therapeutic targets in celiac disease. We characterized the PD1 mRNA variants' profile in CD patients and in response to gluten peptides' incubation after in vitro experiments. Total RNA from whole blood was isolated, and the coding region of the human PD-1 mRNA was amplified by cDNA PCR. PCR amplification of the human PD-1 coding sequence revealed an association between the over-expression of the sPD-1 protein and the PD-1Δex3 transcript in celiac disease. Thus, we have found three novel alternative spliced isoforms, two of which result in a truncated protein and the other isoform with a loss of 14 aa of exon 2 and complete exon 3 (Δ3) which could encode a new soluble form of PD1 (sPD-1). Our study provides evidence that dietary gluten can modulate processes required for cell homeostasis through the splicing of pre-mRNAs encoding key regulatory proteins, which represents an adaptive mechanism in response to different nutritional conditions.
dc.identifier.doi10.3389/fimmu.2021.678400
dc.identifier.essn1664-3224
dc.identifier.pmcPMC8242946
dc.identifier.pmid34220824
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242946/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.678400/pdf
dc.identifier.urihttp://hdl.handle.net/10668/18158
dc.journal.titleFrontiers in immunology
dc.journal.titleabbreviationFront Immunol
dc.language.isoen
dc.organizationHospital Universitario Virgen de las Nieves
dc.page.number678400
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectPD1/PDL
dc.subjectalternative splicing
dc.subjectceliac disease
dc.subjectgluten peptides
dc.subjectimmune checkpoint
dc.subject.meshAlternative Splicing
dc.subject.meshB7-H1 Antigen
dc.subject.meshBiomarkers
dc.subject.meshCeliac Disease
dc.subject.meshChild
dc.subject.meshCytokines
dc.subject.meshDisease Susceptibility
dc.subject.meshFemale
dc.subject.meshGene Expression Regulation
dc.subject.meshHumans
dc.subject.meshImmunohistochemistry
dc.subject.meshInterferon-gamma
dc.subject.meshMale
dc.subject.meshPeptides
dc.subject.meshPolymorphism, Single Nucleotide
dc.subject.meshPrognosis
dc.subject.meshProgrammed Cell Death 1 Ligand 2 Protein
dc.subject.meshProgrammed Cell Death 1 Receptor
dc.subject.meshSignal Transduction
dc.titleSignificance of PD1 Alternative Splicing in Celiac Disease as a Novel Source for Diagnostic and Therapeutic Target.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8242946.pdf
Size:
11.86 MB
Format:
Adobe Portable Document Format